|
|
Volumn 24, Issue 1 SUPPL., 1996, Pages 46-56
|
|
Use of Predicted Risk of Mortality to evaluate the efficacy of anticytokine therapy in sepsis
a,f
|
|
Author keywords
Anticytokine therapy; APACHE III; Clinical trial; Critical illness; Interleukin 1; Outcomes; Risk assessment; Sepsis; Severity of illness index; Tumor necrosis factor
|
|
Indexed keywords
PLACEBO;
RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT;
ADULT;
AGED;
ARTICLE;
CLINICAL TRIAL;
CONTROLLED CLINICAL TRIAL;
CONTROLLED STUDY;
CRITICAL ILLNESS;
DISEASE SEVERITY;
DOUBLE BLIND PROCEDURE;
DRUG EFFICACY;
FEMALE;
HUMAN;
INTRAVENOUS DRUG ADMINISTRATION;
MAJOR CLINICAL STUDY;
MALE;
MODEL;
MORTALITY;
PHASE 3 CLINICAL TRIAL;
PREDICTION;
PRIORITY JOURNAL;
RANDOMIZED CONTROLLED TRIAL;
RISK ASSESSMENT;
SEPSIS;
SURVIVAL TIME;
APACHE;
DOUBLE-BLIND METHOD;
FEMALE;
HUMANS;
INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN;
INTERLEUKIN-1;
MALE;
MIDDLE AGED;
MODELS, STATISTICAL;
RECOMBINANT PROTEINS;
RISK ASSESSMENT;
RISK FACTORS;
ROC CURVE;
SEVERITY OF ILLNESS INDEX;
SIALOGLYCOPROTEINS;
SURVIVAL RATE;
SYSTEMIC INFLAMMATORY RESPONSE SYNDROME;
|
|
EID: 9344240407
PISSN: 00903493
EISSN: None
Source Type: Journal
DOI: 10.1097/00003246-199601000-00010 Document Type: Article |
|
Times cited : (80)
|
|
References (5)
|
